Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

TG Therapeutics, Inc. (TGTX)

Pharmaceutical Preparations

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/14/1995

Market Cap

3,404,557,770

Shares Outstanding

151,410,000

Weighted SO

151,410,073

Total Employees

N/A

Upcoming Earnings

08/06/2024

Similar Tickers

MDGL --.--%

ICPT --.--%

TERN --.--%

HEPA --.--%

EXEL --.--%

VKTX --.--%

BTAI --.--%

AKRO --.--%

RETA --.--%

Beta

2.2290

Last Div

0.0000

Range

6.46-23.12

Chg

1.0500

Avg Vol

2734487

Mkt Cap

3404557770

Exch

NASDAQ

Country

US

Phone

212 554 4484

DCF Diff

17.7578

DCF

-0.1778

Div Yield

0.0000

P/S

9.8192

EV Multiple

33.6388

P/FV

17.9230

Div Yield %

0.0000

P/E

33.2604

PEG

0.9393

Payout

0.0000

Current Ratio

3.5812

Quick Ratio

2.8336

Cash Ratio

0.7630

DSO

88.0145

DIO

1169.5865

Op Cycle

1257.6010

DPO

1345.6370

CCC

-88.0360

Gross Margin

0.9269

Op Margin

0.2937

Pretax Margin

0.2762

Net Margin

0.2760

Eff Tax Rate

-0.0004

ROA

0.2385

ROE

-0.3821

ROCE

0.3481

NI/EBT

0.9990

EBT/EBIT

0.9404

EBIT/Rev

0.2937

Debt Ratio

0.2588

D/E

0.5848

LT Debt/Cap

0.3661

Total Debt/Cap

0.3690

Int Coverage

8.2067

CF/Debt

0.6531

Equity Multi

2.2595

Rec Turnover

4.1470

Pay Turnover

0.2712

Inv Turnover

0.3121

FA Turnover

45.2468

Asset Turnover

0.8642

OCF/Share

0.4686

FCF/Share

0.4686

Cash/Share

1.5011

OCF/Sales

0.1956

FCF/OCF

1.0000

CF Coverage

0.6531

ST Coverage

51.9319

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

17.9230

P/B

17.9230

P/S

9.8192

P/E

33.2604

P/FCF

50.1977

P/OCF

46.9245

P/CF

46.9245

PEG

0.9393

P/S

9.8192

EV Multiple

33.6388

P/FV

17.9230

DPS

0.0000

Latest Headlines (EST)

Benzinga Mar 09, 17:19 Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? Benzinga Jan 11, 12:00 HC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know GlobeNewswire Inc. Jan 05, 07:30 TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Benzinga Dec 06, 14:43 Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session GlobeNewswire Inc. Nov 27, 07:30 TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. Nov 03, 07:30 TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference The Motley Fool Nov 01, 12:18 Why TG Therapeutics Stock Is Crushing It Today GlobeNewswire Inc. Nov 01, 07:30 TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Revenue Product Segmentation